LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="T Kennedy, Patrick"
  2. AU="Cheng, XiaoQing"
  3. AU="Onwuteaka-Philipsen, Bregje D"
  4. AU="Robert D. Welch"
  5. AU="Forget, Francois"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

    Bermingham, Sarah L / Hughes, Ralph / Fenu, Elisabetta / Sawyer, Laura M / Boxall, Elizabeth / T Kennedy, Patrick / Dusheiko, Geoff / Hill-Cawthorne, Grant / Thomas, Howard

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

    2015  Band 18, Heft 6, Seite(n) 800–809

    Abstract: Background: Seven drugs are licensed for the treatment of chronic hepatitis B (CHB) in the United Kingdom. Which initial treatment, secondary therapy, and whether antivirals should be given alone or in combination are questions of considerable ... ...

    Abstract Background: Seven drugs are licensed for the treatment of chronic hepatitis B (CHB) in the United Kingdom. Which initial treatment, secondary therapy, and whether antivirals should be given alone or in combination are questions of considerable uncertainty.
    Objective: The aim of this model was to undertake a comprehensive economic evaluation of all antiviral treatments for CHB to recommend the most cost-effective therapeutic sequence.
    Methods: We developed a probabilistic Markov model to compare the cost-effectiveness of all clinically relevant antiviral treatment sequences for nucleos(t)ide-naive adults with hepatitis B e-antigen (HBeAg)-positive or HBeAg-negative CHB. Relative rates of HBeAg seroconversion and viral suppression were obtained from a network meta-analysis. Data on mortality, antiviral drug resistance, durability of response, adverse events, and costs were obtained from published literature. Results are reported in terms of lifetime costs, quality-adjusted life-years (QALYs), and expected net benefit.
    Results: In the base-case analysis, pegylated interferon alpha-2a (peg-IFN α-2a) followed by tenofovir disoproxil fumarate was most effective and cost-effective in HBeAg-positive patients, with a cost of £7488 per QALY gained compared with no treatment. In HBeAg-negative patients, peg-IFN α-2a followed by entecavir was most effective and cost-effective, with a cost of £6981 per QALY gained. The model was robust to a wide range of sensitivity analyses.
    Conclusions: Peg-IFN α-2a followed by tenofovir disoproxil fumarate or entecavir is the most effective antiviral treatment strategy for people with both variants of CHB. At a cost of less than £10,000 per QALY gained, these sequences are considered cost-effective in England and Wales. The results of this analysis were used to inform 2013 National Institute for Health and Care Excellence guideline recommendations.
    Mesh-Begriff(e) Adult ; Antiviral Agents/economics ; Antiviral Agents/therapeutic use ; Biomarkers/blood ; Comparative Effectiveness Research ; Cost-Benefit Analysis ; Decision Support Techniques ; Drug Costs ; Drug Substitution/economics ; Drug Therapy, Combination/economics ; Female ; Hepatitis B e Antigens/blood ; Hepatitis B, Chronic/blood ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Hepatitis B, Chronic/economics ; Humans ; Male ; Markov Chains ; Models, Economic ; Patient Selection ; Practice Guidelines as Topic ; Probability ; Quality of Life ; Quality-Adjusted Life Years ; State Medicine/economics ; Time Factors ; Treatment Outcome ; United Kingdom ; Young Adult
    Chemische Substanzen Antiviral Agents ; Biomarkers ; Hepatitis B e Antigens
    Sprache Englisch
    Erscheinungsdatum 2015-09
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article ; Meta-Analysis
    ZDB-ID 1471745-1
    ISSN 1524-4733 ; 1098-3015
    ISSN (online) 1524-4733
    ISSN 1098-3015
    DOI 10.1016/j.jval.2015.05.007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels

    Salpini, Romina / Battisti, Arianna / Piermatteo, Lorenzo / Carioti, Luca / Anastasiou, Olympia E / Gill, Upkar S / Di Carlo, Domenico / Colagrossi, Luna / Duca, Leonardo / Bertoli, Ada / La Rosa, Katia Yu / Fabeni, Lavinia / Iuvara, Alessandra / Malagnino, Vincenzo / Cerva, Carlotta / Lichtner, Miriam / Mastroianni, Claudio M / De Sanctis, Giuseppe Maria / Paoloni, Maurizio /
    Marignani, Massimo / Pasquazzi, Caterina / Iapadre, Nerio / Parruti, Giustino / Vecchiet, Jacopo / Sarmati, Loredana / Andreoni, Massimo / Angelico, Mario / Grelli, Sandro / T Kennedy, Patrick / Verheyen, Jens / Aquaro, Stefano / Silberstein, Francesca Ceccherini / Perno, Carlo Federico / Svicher, Valentina

    Emerging microbes & infections

    2020  Band 9, Heft 1, Seite(n) 928–939

    Abstract: Increasing evidences suggest that HBsAg-production varies across HBV-genotypes. HBsAg C-terminus plays a crucial role for HBsAg-secretion. Here, we evaluate HBsAg-levels in different HBV-genotypes in HBeAg-negative chronic infection, the correlation of ... ...

    Abstract Increasing evidences suggest that HBsAg-production varies across HBV-genotypes. HBsAg C-terminus plays a crucial role for HBsAg-secretion. Here, we evaluate HBsAg-levels in different HBV-genotypes in HBeAg-negative chronic infection, the correlation of specific mutations in HBsAg C-terminus with HBsAg-levels
    Mesh-Begriff(e) Adult ; Female ; Genotype ; Hepatitis B Surface Antigens/analysis ; Hepatitis B Surface Antigens/genetics ; Hepatitis B virus/genetics ; Hepatitis B virus/pathogenicity ; Hepatitis B, Chronic/diagnosis ; Humans ; Male ; Middle Aged ; Mutation
    Chemische Substanzen Hepatitis B Surface Antigens
    Sprache Englisch
    Erscheinungsdatum 2020-04-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2020.1757998
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang